This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Accolade, Inc. Promotes Kelsi McDonald Harris to Chief People Officer and Senior Vice President CI
Transcript : Accolade, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM
Leerink Partners Initiates Accolade at Outperform Rating With $16 Price Target MT
Accolade Insider Sold Shares Worth $1,554,504, According to a Recent SEC Filing MT
Transcript : Accolade, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM
Accolade Shares Surge After Raymond James Upgrade, Fiscal Q3 Results MT
Raymond James Adjusts Accolade's Price Target to $16 From $12, Keeps Outperform Rating MT
Accolade Fiscal Q3 Loss Halves, Sales Jump; Issues Guidance MT
Transcript : Accolade, Inc., Q3 2024 Earnings Call, Jan 08, 2024
Accolade, Inc. Provides Earnings Guidance for the Fourth Quarter and Year Ending February 29, 2024 and Year Ending February 28, 2025 CI
Accolade Guides For Q4 Revenue of $121.5-$125.5 Million, vs CIQ Analyst Consensus of $126.4 Million MT
Accolade, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023 CI
North American Morning Briefing : Boeing Drags Down Dow Futures DJ
Stifel Cuts Accolade's Price Target to $15 From $17, Keeps Buy Rating MT
Piper Sandler Adjusts Accolade's Price Target to $12 From $15, Maintains Overweight Rating MT
Accolade to Repurchase $76.5 Million of Outstanding Debt MT
U.S. employers covering weight-loss drugs could nearly double in 2024 - survey RE
Canaccord Genuity Adjusts Accolade Price Target to $17 From $18, Maintains Buy Rating MT
Truist Securities Adjusts Price Target on Accolade to $15 From $17, Keeps Buy Rating MT
Raymond James Adjusts Price Target on Accolade to $12 From $15, Keeps Outperform Rating MT
Accolade Reports Narrowing Net Loss in Fiscal Q2 as Sales Increase MT
Accolade, Inc. Provides Earnings Guidance for the Third Quarter and Full Fiscal Year 2024 CI
Transcript : Accolade, Inc., Q2 2024 Earnings Call, Oct 04, 2023
Accolade, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2023 CI
North American Morning Briefing : S&P 500 Futures -2- DJ
Chart Accolade, Inc.
More charts
Accolade, Inc. provides personalized, technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. Its customers are primarily employers that deploy Accolade solutions in order to provide employees and their families with a single place to turn for their health, healthcare, and benefits needs. It also offers medical opinion services to commercial customers and virtual primary care and mental health support. Its platform, True Health Engine, combines open, cloud-based intelligent technology with multimodal support from a team of empathetic and knowledgeable Accolade Health Assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. Its offerings include Accolade Expert MD, Accolade Care, Plus and Connect and Accolade One.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
8.7 USD
Average target price
15.07 USD
Spread / Average Target
+73.18%
Consensus
  1. Stock Market
  2. Equities
  3. ACCD Stock
  4. News Accolade, Inc.
  5. Jefferies Downgrades Accolade to Hold From Buy, Price Target is $14